Last reviewed · How we verify
NCT06663904: AMRI; LIRADS
Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis
trial in Hepatocellular Carcinoma (HCC) in 938 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | First Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 938 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Conditions studied
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Who can join
18 and older, any sex, with Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Abbreviated MRI (AMRI) could improve the diagnostic performance of hepatocellular carcinoma (HCC), but it lacks analysis in different subgroups and effective validation. The investigators aimed to compare and validate the diagnostic performance of different AMRI protocols in diagnosing early-stage HCC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Diagnosis of Hepatocellular Carcinoma Using Gadoxetic Acid-Enhanced MRI Based on LI-RADS Version 2018 and LI-RADS Modifications.
Qin Y, Zhang J, Xu D, Zhou X, et al · · 2025 · PMID 41042775 · DOI 10.1111/liv.70366
Verify or expand the search:
- PubMed search for NCT06663904
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma (HCC)
Currently open trials in the same condition.
- NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
- NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
- NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting
Other First Affiliated Hospital, Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07322835 — Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China · not yet recruiting
- NCT07322848 — DEB-TACE vs cTACE in HCC After TIPS · Phase 3 · recruiting
- NCT07087418 — AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases · recruiting
- NCT07014475 — Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI · not yet recruiting
- NCT06951334 — Clinical Trial of Vildagliptin in Early Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06663904 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital, Sun Yat-Sen University
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06663904.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing